Research output

Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

Associated organisations

Abstract

There is ample evidence that phosphodiesterase 4 (PDE4) inhibition can improve memory performance in animal studies. In the present study, we examined the acute effects of the PDE4 inhibitor roflumilast on memory performance in healthy individuals (60-80 years of age). We tested the effects of acute roflumilast administration (100, 250, 1000 μg) in a double-blind, placebo-controlled, 4-way crossover design. Participants were first screened for their verbal word memory performance to ensure normal memory performance (within 0.5 standard deviation from norm score; n = 20) Drug effects on memory performance were tested in a verbal memory test and a spatial memory test. Reported side effects of drug treatment were registered. Roflumilast (100 μg) improved the delayed recall performance of the participants (Cohen's d, 0.69). No effects were observed in the spatial memory task. Roflumilast was well tolerated at this low dose. Although no clear adverse side effects were reported at the low dose, mild adverse events (including headache, dizziness, insomnia, and diarrhea) were reported after the 1000 μg dose. The present study provides first evidence that the PDE4 inhibitor roflumilast improves verbal memory performance in old participants. The current data encourage further development of PDE4 inhibitors for improving memory.

    Research areas

  • AGE, Aging, CAMP, COGNITION, Cognition enhancement, DISEASE, EDUCATION, ENHANCEMENT, LONG-TERM-MEMORY, N-OXIDE, NORMATIVE DATA, PHOSPHODIESTERASE-4 INHIBITOR, ROLIPRAM, Verbal memory
View graph of relations

Details

Original languageEnglish
Pages (from-to)37-43
Number of pages7
JournalNeurobiology of Aging
Volume77
Early online date26 Jan 2019
DOIs
Publication statusPublished - May 2019